Risks are increasing, particularly with combination.

So now we're going to test your understanding of some of the concepts that we've put forward.

And our first question here is a man with advanced prostate cancer is having an AR pathway inhibitor such as abiraterone or enzalutamide added to his ADT.

What effect does adding this drug have on his heart risk? So decreases blood pressure and risk of cardiovascular events increases the risk of cardiovascular events and hypertension.

increases cancer control no measurable effect on cardiovascular events or decreases cardiovascular risk by protecting against plaque buildup so all of you have the ability to answer this question and as your answers come in we'll go ahead and put up the poll All right, so the correct answer is those medications, enzalutamide, abiraterine, they would increase cardiovascular events and increase risk of hypertension.

And it looks like the majority felt that that was true too.

All right, let's move to the next slide here.

I always wanted to ask is how frequently do they need to come back and see cardiology?

Risks are increasing, particularly with combination.

So now we're going to test your understanding of some of the concepts that we've put forward.

And our first question here is a man with advanced prostate cancer is having an AR pathway inhibitor such as abiraterone or enzalutamide added to his ADT.

What effect does adding this drug have on his heart risk? So decreases blood pressure and risk of cardiovascular events increases the risk of cardiovascular events and hypertension.

increases cancer control no measurable effect on cardiovascular events or decreases cardiovascular risk by protecting against plaque buildup so all of you have the ability to answer this question and as your answers come in we'll go ahead and put up the poll All right, so the correct answer is those medications, enzalutamide, abiraterine, they would increase cardiovascular events and increase risk of hypertension.

And it looks like the majority felt that that was true too.

All right, let's move to the next slide here.

I always wanted to ask is how frequently do they need to come back and see cardiology?

Risks are increasing, particularly with combination.

So now we're going to test your understanding of some of the concepts that we've put forward.

And our first question here is a man with advanced prostate cancer is having an AR pathway inhibitor such as abiraterone or enzalutamide added to his ADT.

What effect does adding this drug have on his heart risk? So decreases blood pressure and risk of cardiovascular events increases the risk of cardiovascular events and hypertension.

increases cancer control no measurable effect on cardiovascular events or decreases cardiovascular risk by protecting against plaque buildup so all of you have the ability to answer this question and as your answers come in we'll go ahead and put up the poll All right, so the correct answer is those medications, enzalutamide, abiraterine, they would increase cardiovascular events and increase risk of hypertension.

And it looks like the majority felt that that was true too.

All right, let's move to the next slide here.

I always wanted to ask is how frequently do they need to come back and see cardiology?